Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Osteosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 25 May 2017 New trial record